JP2024520481A5 - - Google Patents
Info
- Publication number
- JP2024520481A5 JP2024520481A5 JP2023573047A JP2023573047A JP2024520481A5 JP 2024520481 A5 JP2024520481 A5 JP 2024520481A5 JP 2023573047 A JP2023573047 A JP 2023573047A JP 2023573047 A JP2023573047 A JP 2023573047A JP 2024520481 A5 JP2024520481 A5 JP 2024520481A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- cycloalkyl
- haloalkyl
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163193990P | 2021-05-27 | 2021-05-27 | |
| US63/193,990 | 2021-05-27 | ||
| PCT/US2022/031141 WO2022251502A1 (en) | 2021-05-27 | 2022-05-26 | Checkpoint kinase 1 (chk1) inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520481A JP2024520481A (ja) | 2024-05-24 |
| JP2024520481A5 true JP2024520481A5 (enExample) | 2025-06-02 |
Family
ID=84229213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023573047A Pending JP2024520481A (ja) | 2021-05-27 | 2022-05-26 | チェックポイントキナーゼ１（ｃｈｋ１）阻害剤およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11707462B2 (enExample) |
| EP (1) | EP4347582A4 (enExample) |
| JP (1) | JP2024520481A (enExample) |
| KR (1) | KR20240021188A (enExample) |
| CN (1) | CN117715905A (enExample) |
| AU (1) | AU2022282384A1 (enExample) |
| BR (1) | BR112023024571A2 (enExample) |
| CA (1) | CA3219348A1 (enExample) |
| IL (1) | IL308759A (enExample) |
| MX (1) | MX2023014028A (enExample) |
| TW (1) | TW202313588A (enExample) |
| WO (1) | WO2022251502A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4196614A4 (en) | 2020-08-12 | 2024-12-18 | Boundless Bio, Inc. | COMPOSITIONS OF REPLICATION STRESS SIGNAL PATHWAYS AND METHODS FOR TREATING CANCER |
| MX2023006364A (es) | 2020-11-30 | 2023-06-13 | Sumitomo Pharma Co Ltd | Derivado de 5-heteroaril-1h-pirazol-3-amina. |
| JP2024520481A (ja) | 2021-05-27 | 2024-05-24 | バウンドレス バイオ，インク． | チェックポイントキナーゼ１（ｃｈｋ１）阻害剤およびその使用 |
| EP4455134A4 (en) * | 2021-12-24 | 2025-10-08 | Sumitomo Pharma Co Ltd | 1H-PYRAZOLE-3-AMINE DERIVATIVE HAVING A BICYCLIC SKELETON |
| IL317138A (en) * | 2022-05-24 | 2025-01-01 | Boundless Bio Inc | Pyridine checkpoint kinase 1 (CHK1) inhibitors and their uses |
| WO2023226658A1 (en) * | 2022-05-25 | 2023-11-30 | Sperogenix Therapeutics Limited | Nitrogen-containing five-membered heterocyclic derivatives as checkpoint kinase 1 inhibitor and uses thereof |
| TW202440549A (zh) * | 2022-11-29 | 2024-10-16 | 美商無界生物公司 | 檢查點激酶１（ｃｈｋ１）抑制劑及其用途 |
| EP4626433A1 (en) * | 2022-11-29 | 2025-10-08 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof |
| WO2024196923A1 (en) * | 2023-03-20 | 2024-09-26 | Boundless Bio, Inc. | Uses of a checkpoint kinase 1 (chk1) inhibitor |
| WO2024211271A1 (en) * | 2023-04-03 | 2024-10-10 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor pharmaceutical composition |
| WO2024211270A1 (en) * | 2023-04-03 | 2024-10-10 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor crystalline form and uses thereof |
| WO2025030049A1 (en) * | 2023-08-02 | 2025-02-06 | Health Research, Inc. | Sequential treatment method for p53-deficient cancer |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0110302A (pt) * | 2000-04-18 | 2003-01-14 | Agouron Pharma | Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase |
| NZ523656A (en) * | 2000-08-31 | 2004-11-26 | Pfizer Prod Inc | Pyrazole derivatives and their use as protein kinase inhibitors |
| US20050209297A1 (en) * | 2000-08-31 | 2005-09-22 | Pfizer Inc | Pyrazole derivatives |
| PA8850801A1 (es) * | 2008-12-17 | 2010-07-27 | Lilly Co Eli | Compuestos útiles para inhibir chk1 |
| GB201402277D0 (en) * | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CN108601781B (zh) * | 2016-02-04 | 2019-11-22 | 广州必贝特医药技术有限公司 | 作为检测点激酶1(chk1)抑制剂的3,5-二取代吡唑及其制备及应用 |
| CN114728949B (zh) * | 2019-08-01 | 2024-11-12 | 曙方医药 | 作为激酶抑制剂的杂环化合物及其用途 |
| CN112457306A (zh) * | 2019-09-06 | 2021-03-09 | 上海瑛派药业有限公司 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
| CN111253370B (zh) | 2020-03-24 | 2021-08-03 | 浙江大学 | N-多取代吡啶-2-氨基嘧啶类衍生物及用途 |
| MX2023000150A (es) * | 2020-06-19 | 2023-03-22 | Anaxis Pharma Pty Ltd | Compuesto de sulfonamida. |
| EP4196614A4 (en) | 2020-08-12 | 2024-12-18 | Boundless Bio, Inc. | COMPOSITIONS OF REPLICATION STRESS SIGNAL PATHWAYS AND METHODS FOR TREATING CANCER |
| JP2023547396A (ja) | 2020-10-23 | 2023-11-10 | セルジーン コーポレーション | 蠕虫感染及び疾患の処置のための複素環式化合物及びその使用 |
| MX2023006364A (es) * | 2020-11-30 | 2023-06-13 | Sumitomo Pharma Co Ltd | Derivado de 5-heteroaril-1h-pirazol-3-amina. |
| US11564920B2 (en) | 2020-11-30 | 2023-01-31 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1H-pyrazol-3-amine derivative |
| JP2024520481A (ja) | 2021-05-27 | 2024-05-24 | バウンドレス バイオ，インク． | チェックポイントキナーゼ１（ｃｈｋ１）阻害剤およびその使用 |
| EP4455134A4 (en) | 2021-12-24 | 2025-10-08 | Sumitomo Pharma Co Ltd | 1H-PYRAZOLE-3-AMINE DERIVATIVE HAVING A BICYCLIC SKELETON |
| IL317138A (en) | 2022-05-24 | 2025-01-01 | Boundless Bio Inc | Pyridine checkpoint kinase 1 (CHK1) inhibitors and their uses |
| WO2023226658A1 (en) | 2022-05-25 | 2023-11-30 | Sperogenix Therapeutics Limited | Nitrogen-containing five-membered heterocyclic derivatives as checkpoint kinase 1 inhibitor and uses thereof |
| CN119403571A (zh) | 2022-05-27 | 2025-02-07 | 住友制药株式会社 | 对免疫检查点抑制剂示出治疗抗性的癌症的治疗药 |
| TW202440549A (zh) | 2022-11-29 | 2024-10-16 | 美商無界生物公司 | 檢查點激酶１（ｃｈｋ１）抑制劑及其用途 |
| EP4626433A1 (en) | 2022-11-29 | 2025-10-08 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof |
| WO2024196923A1 (en) | 2023-03-20 | 2024-09-26 | Boundless Bio, Inc. | Uses of a checkpoint kinase 1 (chk1) inhibitor |
| WO2024211271A1 (en) | 2023-04-03 | 2024-10-10 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor pharmaceutical composition |
| WO2024211270A1 (en) | 2023-04-03 | 2024-10-10 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor crystalline form and uses thereof |
-
2022
- 2022-05-26 JP JP2023573047A patent/JP2024520481A/ja active Pending
- 2022-05-26 AU AU2022282384A patent/AU2022282384A1/en active Pending
- 2022-05-26 IL IL308759A patent/IL308759A/en unknown
- 2022-05-26 BR BR112023024571A patent/BR112023024571A2/pt unknown
- 2022-05-26 TW TW111119737A patent/TW202313588A/zh unknown
- 2022-05-26 CA CA3219348A patent/CA3219348A1/en active Pending
- 2022-05-26 EP EP22812165.3A patent/EP4347582A4/en active Pending
- 2022-05-26 WO PCT/US2022/031141 patent/WO2022251502A1/en not_active Ceased
- 2022-05-26 CN CN202280052765.2A patent/CN117715905A/zh active Pending
- 2022-05-26 MX MX2023014028A patent/MX2023014028A/es unknown
- 2022-05-26 KR KR1020237044236A patent/KR20240021188A/ko active Pending
- 2022-08-29 US US17/897,667 patent/US11707462B2/en active Active
-
2023
- 2023-06-01 US US18/327,775 patent/US12527790B2/en active Active